author-photo

D. Ciardiello

25

Papers

142

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

EPV187/#241 Efficacy of parp inhibitors maintenance in older patients with ovarian cancer: a meta-analysis

2021
Show All
- Source
- Cite
- Save
Citations (0)
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'.

2020
Show All
- Source
- Cite
- Save
Citations (9)
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (40)
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations:

2020 Therapeutic Advances in Medical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
11PTriple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P-326Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
668TiPPhase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
121PAXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)